COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05249829

Not reported

Not reported

2022-02-22

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test at the screening visit and on the day of vaccination prior to vaccine dose being administered on day 1; has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (day 1); and has agreed to continue adequate contraception through 90 days following vaccine administration. participant has received 2 prior doses of one of the following approved/authorized covid-19 vaccines: moderna, pfizer/biontech, oxford/astrazeneca, janssen. a heterologous vaccine regimen is acceptable. participants who will receive the 4th dose as part of the study must have previously received a mrna vaccine (moderna or pfizer/biontech) as the 3rd dose of a covid-19 vaccine. participants who will receive the 3rd dose as part of the study may have previously received 2 doses of an approved/authorized mrna or a non-mrna covid-19 vaccine (a heterologous vaccine regimen is acceptable).

participant had close contact (without personal protective equipment [ppe]) as defined by the centers for disease control and prevention (cdc) in the past 14 days to someone diagnosed with sars-cov-2 infection or covid-19 within 10 days of the close contact. participants may be rescreened after 14 days provided that they remain asymptomatic. participant is acutely ill or febrile (temperature ≥ 38.0°c/100.4°f) 72 hours prior to or at the screening visit or day 1. participant has tested positive for sars-cov-2 by an authorized/approved lateral flow/rapid antigen or polymerase chain reaction (pcr) test within 90 days of screening. participant has received a covid-19 vaccine within 90 days of the screening visit. participant has received a total of 4 doses or more of covid-19 vaccine. participant has received a covid-19 vaccine at a dose different from the authorized/approved dose. any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 181 days prior to screening (for corticosteroids ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. participant has received or plans to receive any licensed vaccine ≤28 days prior to the study injection (day 1) or plans to receive a licensed vaccine within 28 days after the study injection (with the exception that approved seasonal influenza vaccine may be received by at least 7 days and preferably 14 days apart from the study injection). participant has received systemic immunoglobulins or blood products within 90 days prior to the screening visit or plans to receive during the study. participant has donated ≥450 milliliters (ml) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study. participant has participated in an interventional clinical study within 28 days prior to the screening visit based on the medical history interview or plans to do so while participating in this study. note: other inclusion and exclusion criteria may apply.

4

ModernaTX, Inc.

16

100

United Kingdom

Healthy volunteers

N/A

3557

Geometric Mean Titer (GMT) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain;GMT of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain;GMT of mRNA-1273.214 and mRNA-1273 Against the Prototype Strain;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Medically Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)

None

Phase 2/Phase 3

[{"arm_notes": "nan", "treatment_id": 2176, "treatment_name": "Mrna-1273.529", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Comparator Part 1", "treatment_id": 824, "treatment_name": "Mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nan", "treatment_id": 2441, "treatment_name": "Mrna-1273.214", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Comparator Part 1", "treatment_id": 824, "treatment_name": "Mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]